Company / PP&E (Net)
10x Genomics, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$226.7M
FY2025
5-year range
$169.5M / $289.3M
FY2021-FY2025
Trend
-10.3%
vs FY2024
Sector context
#67 of 135
Health Care
What the data says
At $227M, 10x Genomics, Inc.'s pp&e (net) ranks #67 of 135 in the Health Care sector. PP&E (Net) has declined for 3 consecutive years, from $289M in FY2022 to $227M in FY2025.
Based on SEC 10-K filings.
$227M in FY2025 with a 5-year CAGR of +25.5%.
Declined from $280M to $227M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -7.8%
- 5-Year CAGR
- +25.5%
- 10-Year CAGR
- -
Sector benchmark
#67 of 135 in Health CareTop 50% of 135This company $226.7M Sector average $1.4B
▼
-83.4% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +25.5%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 10.3% year-over-year.
- Ranks #67 out of 135 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $226.7M | -10.3% |
| FY2024 | $252.6M | -9.6% |
| FY2023 | $279.6M | -3.4% |
| FY2022 | $289.3M | +70.7% |
| FY2021 | $169.5M | +132.7% |
| FY2020 | $72.8M | +49.2% |
| FY2019 | $48.8M | +338.8% |
| FY2018 | $11.1M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026